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Abstract Evaluations of healthcare interventions, e.g.
new drugs or other new treatment strategies, commonly
include a cost-effectiveness analysis (CEA) that is based on
the application of health economic (HE) models. As end
users, patients are important stakeholders regarding the
outcomes of CEAs, yet their knowledge of HE model
development and application, or their involvement therein,
is absent. This paper considers possible benefits and risks
of patient involvement in HE model development and
application for modellers and patients. An exploratory
review of the literature has been performed on stakeholder-
involved modelling in various disciplines. In addition,
Dutch patient experts have been interviewed about their
experience in, and opinion about, the application of HE
models. Patients have little to no knowledge of HE models
and are seldom involved in HE model development and
application. Benefits of becoming involved would include a
greater understanding and possible acceptance by patients
of HE model application, improved model validation, and a
more direct infusion of patient expertise. Risks would
include patient bias and increased costs of modelling.
Patient involvement in HE modelling seems to carry sev-
eral benefits as well as risks. We claim that the benefits
may outweigh the risks and that patients should become
involved.
Key Points for Decision Makers
Health economic models play an important role in
assessments of healthcare interventions.
Patients are important stakeholders who can add to
health economic modelling.
Ways of involving patients in health economic
modelling should be explored further.
1 Introduction
Health technology assessment (HTA) has been used as a
way to limit the trend of increasing healthcare expenditures
in many European countries since the 1990s [1, 2]. Many
countries use cost effectiveness as an important formal
(e.g. Austria, Belgium, the Netherlands, and Sweden) or
informal (e.g. France) criterion for HTA information in
their evaluation process [3]. The clearest example is pro-
vided by the UK, where official thresholds for cost effec-
tiveness play a structured role [4].
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Many cost-effectiveness analyses (CEAs) use health
economic (HE) models to obtain estimates of costs and
benefits of new interventions. Validation (the evaluation of
‘whether [a] model is a proper and sufficient representation
of the system it is intended to represent’ [5]) is therefore
emphasized by guidelines on good HE modelling practice
[6–11]. These guidelines mostly cover the scientific cred-
ibility of the models. Experience from other fields like
climate research, nature policy assessments, and water
management shows that validation also entails other
aspects related to fitness for purpose. These are stakeholder
perception of model salience (model applicability within
the context) and legitimacy (the inclusion of stakeholder
concerns, values and views in a proper way) [12]. Hence,
stakeholder involvement is considered to be a critical
aspect of good modelling practice [12–21].
Patients are one group of stakeholders that is obviously
important in terms of HTA decisions. But while the vali-
dation of HE models has become a point of progression in
HE literature, the involvement of patients in modelling
appears to remain underappreciated. HE models play an
implicit role by providing relevant information for the
reimbursement decision process. However, they often are a
‘black box’ to patients, and one can argue there may be a
moral obligation to further open this ‘black box’ and
involve patients in the development and application of HE
models. Moreover, many patients have become experts
who can provide valuable information for HE modellers.
Their involvement could improve the credibility, salience
and legitimacy of HE models. The relevance of this issue is
even higher as HE models are used in the early stages of
HTA, affecting the downstream drug-evaluation processes.
In this opinion paper, we discuss benefits and risks of
patient involvement in HE model development and appli-
cation as well as possible ways of involving patients. We
conducted an exploratory literature search to gain insight
into the issues at stake and arguments applied. An exten-
sive literature exists about stakeholder involvement in
modelling, but only few studies report on the current area
of interest (HE decision modelling). In addition, discus-
sions were held with patient experts (see the Sect. 6 for
more details). In this paper, double quotes (‘‘…’’) indicate
arguments made by these patient experts (where it has been
attempted to retain as much as possible of the original
meaning in the translation from Dutch to English).
2 Why Involve Patients in Health Economic (HE)
Modelling?
We distinguish between arguments in favour of patient
involvement based on improving model credibility, sal-
ience and legitimacy [12].
Model credibility can be improved by communication
about uncertainties in the model design and the inclusion or
exclusion of factors (such as side effects, time horizon, or
capturing of cost, to name a few). The few patients who are
aware of HE modelling feel like ‘‘health care calculations
are too narrow, excluding various second-order costs and
benefits from treatments,’’ as ‘‘there are many patients that
suffer from several chronic diseases simultaneously, and
for whom CEAs could be positive that are otherwise neg-
ative.’’ Patient involvement can improve mutual under-
standing and model designs. Patient involvement ‘‘may
make modellers aware of things they have not considered’’
while patients ‘‘ask the naive questions’’ and ‘‘contribute
knowledge about co-occurring diseases and side-effects of
drugs.’’ At the same time ‘‘patients see the calculations and
become more aware of medical costs’’ and learn about the
consequences of model-based decisions [14].
Model salience can be improved by jointly selecting
model performance criteria [15, 16] and appropriate indi-
cators for decision making [15]. For instance, patients
indicate that ‘‘the standardization of patients is a risky
affair, and HE model output should cover patient hetero-
geneity.’’ Confidence limits of model output contain
essential information for patients and modellers alike to
judge the usefulness of the model output for decision
making [13]. The inclusion of ‘policy levers’ that represent
typical options for decision makers [15] and the develop-
ment of computer interfaces for model usability [17] also
improve salience.
Model legitimacy can also improve with patient
involvement. Only few patients are currently aware of the
use or existence of HE models. Patient experts indicate that
they expect that ‘‘HE modellers will be fair and trust-
worthy because of their medical background,’’ but ‘‘there
may be a sort of attic room reality created by modellers.’’
Whether or not this is a valid perception, it indicates that
the legitimacy of HE models can be much improved.
Experience shows that the inclusion of stakeholders can
create a feeling of ‘ownership’ regarding the findings,
while a lack of stakeholder involvement creates a feeling of
‘not invented here’ and a dismissal of (model-based) out-
comes [22], or, in the words of patients, ‘‘We would like to
have a say about what goes into our bodies.’’
3 How Can We Involve Patients in HE Modelling?
Involving patients in HE modelling should maximize the
benefits and minimize the risks. Research on this is needed.
Literature on trans-disciplinary science and stakeholder
involvement in modelling provides guidelines on how to
involve stakeholders [13–15]. These guidelines may or
may not equally apply to patient involvement. The patients
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we interviewed also provided suggestions on what would
be more or less likely to work.
A vital factor for the success of modelling projects is a
continuing inclusion of patients, i.e. from start to finish [13,
14], and with regular interactions between modellers and
patients in which results can be presented, questions can be
asked, and answers and feedback can be given. Patients can
likely be involved in the following modelling aspects [15]:
1. The problem formulation, including the establishment
of a shared terminology and an agreement on the goal
of the model;
2. Setting model performance requirements, based on an
inventory of what is expected of the model in terms of
scientific credibility, its application, and the views,
values and concerns of patients and other stakeholders;
3. The design of the conceptual model, for instance as
was done by the School of Health and Related
Research (ScHARR), UK, through a number of
sessions in which patients participated in the design
phase of the conceptual model of two diabetes-
prevention models [23];
4. Setting model applicability limitations, i.e. it is
understood by patients what the model cannot do;
5. A selection of appropriate indicators for decision
making that are understood by patients; and
6. A discussion about uncertainties in the model, their
effect on model output, and the ramifications of these
uncertainties for decision making.
HE models are most likely to benefit from patients ‘‘who
are capable of abstract thinking and can rise above their
own disease.’’ Patients ‘‘who followed courses on HE
modelling can translate model outcomes for other
patients.’’ At the same time, it is also ‘‘a responsibility of
the modellers to explain their work to patients.’’ Clear and
concise documentation on model assumptions, limitations,
and alternative model designs should be available for
communication between modellers and patients [14, 15].
The discussion between modellers and patients can also
benefit from user interfaces to ‘play’ with the model [17,
18].
4 Risks, Drawbacks, and Limitations
Patient involvement in the HE modelling process may also
be subject to risks, drawbacks, and limitations. Many of
these were indicated by the patients we interviewed.
One obvious limitation is that ‘‘most patients are not
even aware of the use of HE models.’’ They ‘‘recognize the
evaluation process, but not what is before that,’’ i.e. the use
of HE models for HTA. Patients will thus have to be
educated in this regard. A current limitation for education
is mentioned, ‘‘at the moment there is very good docu-
mentation available at the website of Zorginstituut Ne-
derland [the Dutch National Health Care Institute that
advises the Dutch government with regard to reimburse-
ment decisions], but one cannot access material about HE
models used in CEAs.’’
A second important limitation is that patient involve-
ment will require ‘‘a serious investment in terms of time
and money for patients to get to a level at which they can
really contribute.’’ The same also applies for modellers.
Such an investment of resources is not free of risks and,
furthermore, it is unclear who should supply these resour-
ces in what way. One risk is that ‘‘many patients will not be
suited for [an involvement in HE modelling], as they will
not be able to rise above their disease.’’ It is therefore
indicated that ‘‘we need patients who are able and willing
to dive into this material out of interest, and who can have
an objective view.’’ A proper selection procedure for such
patients will have to be developed.
Despite the additional costs, it is expected that ‘‘the cost-
effectiveness of patient involvement in HE modelling may
be positive in the long run’’ as the benefits eventually
outweigh the initial investment costs. In particular, ‘‘the
involvement of patients may reduce the time before
availability through faster acceptance by the intended users
and an improved knowledge transfer,’’ i.e. the additional
costs of patient involvement may (partly) be recovered
from savings in time or costs further downstream of the
decision process, since the model is more acceptable,
credible and legitimate. In addition, ‘‘there is a lot of
knowledge to share that isn’t made available at the
moment.’’ As patients get educated and develop experience
through being involved in modelling, they ‘‘could play an
important role in the spread of experience and knowledge
that is relevant also for CEAs of different diseases.’’
The inclusion of patients in HE models is a potential
source of bias towards patient views. Such bias could for
instance be that certain side effects are over-emphasized by
involved patient(s). Patients may also be viewed upon as
shilling for certain interventions. Such bias can be avoided
by including patients who are able to take a neutral view,
and by the inclusion of ‘‘at least five patients who differ
significantly in their background.’’
5 Concluding Opinion
Patients are key stakeholders in HE modelling, yet their
involvement is sparse at best. A positive exception is the
ScHARR project [23]. One can argue there is a moral
obligation to involve patients in HE model development
and application because of the hidden impact that HE
model-based decisions can have on their lives. Also, there
Involving Patients in Health Economic Modelling 131
may be significant benefits if patients were to be commonly
involved in modelling. These benefits include an expected
increase in the validation status of HE models through
improved model credibility, salience, and legitimacy,
through a greater understanding and possible acceptance by
patients of HE model applications and a more direct infu-
sion of patient expertise. There are also risks associated
with patient involvement, most notably a possible patient
bias and an increased cost of modelling, at least in the short
run. We believe that the benefits and obligations outweigh
the risks and that the need for patient involvement in HE
modelling is obvious.
What remains is the matter of how to involve patients in
HE modelling in a good way. The involvement of stake-
holders in modelling has rapidly become common in other
scientific disciplines in the past decade (as suggested by the
vast literature on stakeholder involvement in modelling
[12–21]) and, although many issues are mentioned, overall
the effect of stakeholder involvement in modelling seems
to be positive. Yet, the HE modelling field seems to be
lagging behind in this respect when compared with, for
instance, the fields of commerce and defence [24] or
environmental sciences. It seems wasteful to re-invent the
wheel; there are sufficient guidelines on stakeholder-in-
volved modelling in other scientific disciplines that may be
applicable for patient involvement in HE modelling.
Both additional research and investments of resources
are required to establish effective ways of patient
involvement in the field of HE modelling. At the very least,
it requires the training of both modellers and patient
experts to communicate effectively with each other. We
argue that effort should be spent towards these goals.
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Appendix
This opinion paper presents an exploratory spin-off of a
larger project on HE model validation [5]. The references
from outside the HE modelling discipline are based on the
experience and work of the first author in ecological
assessments. This work included a search in Google
Scholar using a combination of the term ‘stakeholder’ with
either ‘modelling’ or ‘assessment’. The 70,000? hits has
been reduced through the use of more advanced terms, such
as ‘participatory modelling’, ‘credibility’, ‘salience’, ‘le-
gitimacy’, and ‘trans-disciplinary science’. References
[12–21] present a very compacted overview of this search
and present important lessons to be learned on stakeholder
involvement that are likely equally relevant for HE
modelling.
In addition, one or more interviews have been conducted
with seven Dutch patient experts (all with a chronic illness)
in different formats (in person, in a focus group, by phone,
and via e-mail) about their experiences with CEAs and
their perceptions on collaboration between patients and HE
modellers. These patients were contacted in a limited
timeframe through advertisements in patient expert groups
active in different areas, and ‘snow-balling’, i.e. patients
who knew patients who might be interested. All inter-
viewed patients indicated they had rather in-depth knowl-
edge of the Dutch drug reimbursement process. They
mostly knew that part of the information they received in
preparing the reimbursement advice was based on HE
models, but indicated that they knew little to nothing about
the particular HE models used. At least one patient had
taken courses on the topic to gain in-depth knowledge of
HE modelling but indicated there is no transparency with
regard to models. The interviewed patients thus represented
a small but appropriate subset of patients who are (poten-
tially) interested in learning about HE model development
and application, who in turn are a subset of patients with
knowledge about the drug reimbursement process in the
Netherlands. Because of the limited, exploratory character
of the research, no systematic efforts were undertaken to
avoid bias of any type (e.g. age, sex, type of illness, etc.).
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